Our previous studies indicated that the release of HMGB1 and infiltration of CD8+ TILs were significantly associated with favorable survival outcomes in colorectal cancer [34,41,42], especially in patients who received the neoCRT regimen [34,41]. This evidence concerns the gene CD8A and colorectal cancer.